Oncolytic virus and PD-1/PD-L1 blockade combination therapy.
Oncolytic virus and PD-1/PD-L1 blockade combination therapy.
复制标题
DOI：
10.2147/ov.s145532
复制
发表时间：
2018
影响因子：
6.7
通讯作者：
Cripe TP
中科院分区：
文献类型：
--
作者：
Chen CY;Hutzen B;Wedekind MF;Cripe TP
溶瘤病毒对许多类型的癌症都是裂解的，但在正常组织中是弱化的或复制缺陷的。除了肿瘤溶解，溶瘤病毒还可以诱导宿主对癌细胞的免疫反应，因此可以被视为一种免疫疗法。尽管最近检查点抑制剂的成功表明增强抗肿瘤免疫是有效的，但免疫抑制肿瘤微环境的动态性质对这些疗法的广泛应用构成了重大障碍。针对一种免疫抑制途径可能不足以消除肿瘤。在这里，我们重点发展溶瘤病毒治疗与检查点抑制剂的结合，旨在靶向程序性细胞死亡蛋白1和程序性细胞死亡配体1信号轴。我们还讨论了这种新的联合疗法临床应用的未来方向。
Oncolytic viruses are lytic for many types of cancers but are attenuated or replication-defective in normal tissues. Aside from tumor lysis, oncolytic viruses can induce host immune responses against cancer cells and may thus be viewed as a form of immunotherapy. Although recent successes with checkpoint inhibitors have shown that enhancing antitumor immunity can be effective, the dynamic nature of the immunosuppressive tumor microenvironment presents significant hurdles to the broader application of these therapies. Targeting one immune-suppressive pathway may not be sufficient to eliminate tumors. Here we focus on the development of the combination of oncolytic virotherapy with checkpoint inhibitors designed to target the programmed cell death protein 1 and programmed cell death ligand 1 signaling axis. We also discuss future directions for the clinical application of this novel combination therapy.